

--This application is a continuation-in-part of U.S. Application Serial No.

09/449,914, filed on December 2, 1999, now U.S. Patent No. 6,235,718, issued May

22, 2001, which is a divisional of U.S. Patent No. 6,013,633, issued January 11, 2000. --

Please delete the paragraph of the specification beginning at page 7, line 1 and replace it with the following rewritten paragraph:

--U.S. Pat. No. 5,328,899, Boublík *et al.*, issued Jul. 12, 1994, discloses

Q2 NPY peptide analogs. Human Neuropeptide Y (NPY) has the formula: H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH₂ (SEQ ID NO:1). Porcine and rat NPY have the same sequence except for Leu instead of Met in the 17-position. Porcine PYY is homologous having 11 different residues. NPY analogs and N-terminally-shortened fragments, e.g. NPY(18-36), which contain one or more specific D-isomer substitutions for the naturally occurring residues (as well as pharmaceutically acceptable salts thereof), dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to substantially lower blood pressure over an extended period of time or to counteract hypertension. --

Please delete the paragraph of the specification beginning at page 9, line 13 and replace it with the following rewritten paragraph:

Q3 --A1 is a D or L-amino acid selected from the group consisting of Cys,

Leu, Dap (1,2-Diaminopropionic acid), Trp, Gln, a tethered amino acid with an indole ring (e.g., N-Me-Trp), Phe, Hyp, any Trp derivative (e.g., 2 chlorotryptophan, or Tcc);

CaMe-Trp, CaMe-Gln, Des-amino-Trp, Pyr (Pyroglutamic acid), Bth, Nal, Tcc, Asn, Nva,
Abu, Tyr, Tic-OH, Phe, Tip (1,2,3,4-tetrahydronorharman-3-carboxylic acid), and Dip.

AB
Conclude

Please delete the paragraph of the specification beginning at page 10, line 10 and replace it with the following rewritten paragraph:

A4
Preferred compounds of formula (I) include those in which A1 is [Try] Trp or a pharmaceutically acceptable salt thereof.

Please amend page 38, line 34 of the specification to read:

A5
-39. (Ac-Cys-Trp-Arg-Tyr-NH₂)₂ (SEQ ID NO: 2)

Please amend page 38, line 36 of the specification to read:

A6
-41. Dap-Ile-Trp-Arg-Glu-Arg-Tyr-NH₂ (SEQ ID NO: 3)

Please amend page 38, line 37 of the specification to read:

A7
-42. Leu-Ile-Trp-Arg-Glu-Arg-Tyr-NH₂ (SEQ ID NO: 4)

Please amend page 38, line 38 of the specification to read:

A8
-43. Cyclo(-Trp-Arg-Nva-Arg-Tyr-) (SEQ ID NO: 5)

Please add enclosed pages 46 and 47 and renumber previous page 46 to read 48.